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Background: Recent discovery of the Th17 pathway is providing new opportunities for understanding chronic
immune-mediated diseases. The Th17 pathway has been historically associated with chronic inflammatory
diseases such as psoriasis, multiple sclerosis, and rheumatoid arthritis. Among Th17 cytokines, pathogenic roles
of IL-17A and IL-17F in asthma have been well described. Recently, the number of peripheral blood Th17 cells
was found to correlate with disease severity in patients with atopic dermatitis (AD). This study aimed to
investigate serum IL-17F levels in children with AD and to correlate this with severity of the disease.
Methods: Enzyme-linked immunosorbent assay was used to measure IL-17F levels in the sera of 228 patients
with AD and 62 control children. The SCORing Atopic Dermatitis (SCORAD) tool was used to determine the
severity of disease.
Results: The mean serum level of IL-17F in children with AD was significantly higher than that in the control
group (p < 0.05) Serum IL-17F levels were also higher in patients with severe AD than in those with mild AD
( p < 0.001), and IL-17F levels and SCORAD scores were positively correlated ( p< 0.05).
Conclusions: Serum IL-17F level might be a useful marker in children with AD.
Introduction
Atopic dermatitis (AD) is a chronic and relapsing in-flammatory skin disease. The pathophysiology of AD is
complex, and has been attributed to the interaction of mul-
tiple genetic, immunologic, and environmental factors. AD
has long been characterized by dermal inflammatory infil-
trates, with a dominant Th2 profile during the acute phase
and a dominant Th1 profile characteristic of the chronic
stage.1 Recent studies suggest that Th17 cells, distinct from
Th1 and Th2 cells, play a role in sustained inflammation in
allergic asthma, another Th2-mediated allergic disease.2
However, the number of Th17 cells present in AD is still
controversial, with both increased and decreased Th17 cells
(compared with controls) reported.3–6 These differences
may arise from the distinct phase of AD, as noted in many
studies. Furthermore, Koga et al. proposed that a reduced
number of circulating Th17 cells may reflect tissue infil-
tration in AD lesions.4
Th17 cells produce cytokine of the Th17 cytokine family,
consisting of six members named IL-17A to IL-17F. In
humans, IL-17A and IL-17F levels have been shown to be
involved in chronic inflammatory diseases such as psoriasis,
multiple sclerosis, and rheumatoid arthritis. Recently, IL-
17F has been reported to activate eosinophils to release
profibrotic cytokines involved in tissue inflammation and
repair.7,8 Increased production of IL-17F has been reported
in stimulated peripheral blood mononuclear cells and
bronchoalveolar lavage fluid from asthmatics.9 Furthermore,
upregulated IL-17F gene expression has been reported at
sites of allergen challenge, and an H161R variant in the IL-
17F gene was associated with protection against asthma in a
cohort from Japan.10 Neutrophil inflammation in the lung,
mediated by IL-17F, was found to be steroid resistant, and
IL-17F-related immune pathology may explain some as-
pects of the heterogeneity in asthma.11 To date, few studies
on the role of IL-17F in the pathogenesis of AD have been
performed. In this study, the association of IL-17F levels in
the sera of children with AD severity was investigated.
Methods
Subjects
The study included 290 children (Mage = 5.50 – 4.06
years; 182 boys) who visited the allergy clinic for AD or a
general health work-up at the Severance Children’s Hospital
from January 2006 to June 2013. AD was defined according
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to the Criteria of Hanifin and Raijka.12 The severity of AD
was determined using the SCORing Atopic Dermatitis
(SCORAD) index system.13 Two pediatric allergists made
the AD diagnosis and performed the SCORAD assessment.
There was no difference in the scoring between the two
pediatricians. In this study, 228 children with AD were
subdivided according to severity of AD, with cases classi-
fied according to SCORAD as mild (<15), moderate (be-
tween 15 and 40) and severe (>40) AD. Of AD cases scored,
129 patients (56.6%) had severe AD, 49 (21.5%) had
moderate AD, and 50 (21.9%) had mild AD. The control
group comprised 62 children (32 boys) with no history of
AD or other allergic disease. At initiation of the study, se-
rum total IgE levels, peripheral blood white blood cells
(WBC), eosinophil counts, and neutrophil counts were de-
termined. Total IgE levels were measured using a fluor-
immunoenzyme assay (the CAP system FEIA; Phamacia &
Upjohn Diagnostic AB, Uppsala Sweden) according to the
manufacturer’s instructions. Specific IgE levels >0.35 kUA/
L were considered positive. A hematology analyzer (NE-
8000; Sysmax, Kobe, Japan) was used to count peripheral
blood WBC, eosinophils, and neutrophils automatically.
This study was approved by Severance Hospital’s Institution
Review Board, and informed consent was obtained from
parents of the children included in this study.
Evaluation of serum interleukin 17F
Blood samples were taken from all participants and sepa-
rated by centrifugation at 400 g for 10min. Serum samples
were stored at -70C until testing. Serum levels of IL-17F
were measured using commercially available enzyme-linked
immunosorbent assay kits (catalog #DY1335; R&D system,
Minneapolis, MN), according to the manufacturer’s instruc-
tions. The minimum detection level of IL-17F was 312 pg/mL.
Statistical analysis
Statistics analysis was conducted with SPSS Statistics
for Windows v20.0 (IBM Corp., Armonk, NY). Data were
compared between groups by Student’s t-test and one-way
analysis of variance. Due to the lack of normal distribution
of peripheral blood WBC, eosinophil count, neutrophil
count, and serum IL-17 level, its values in two and more
subgroups were compared with the Mann–Whitney U-test
and Kruskal–Wallis test. Linear regression was used to
correlate serum IL-17F levels with serum total IgE,
SCORAD, and total eosinophil count. Because the data for
serum total IgE levels in AD patients were not normally
distributed, a logarithmic transformation value was used for
analysis. Age as a confounding factor was adjusted in the
models. A p-value of <0.05 was considered statistically
significant.
Results
Demographics, blood count, and IgE levels
of subjects
Children with AD were younger than the control subjects
(M– SD = 7.93 – 3.9 years vs. 4.84– 3.9 years; p< 0.001).
Children in the severe AD group were older than those in the
moderate AD group (M– SD = 5.36– 4.1 years vs. 3.42– 3.4
years; p = 0.002). There were no significant differences in
the sex ratio between the AD and control groups. Both blood
eosinophil counts and WBC counts (median [interquartile
range]) were significantly different between children with
AD (465/mL [290–770/mL] and 9,080/mL [7,430–11,105/mL])
and controls (170/mL [100–275/mL] and 7,175/mL (6,180–
8,732/mL)], with p< 0.001. For serum total IgE (median [in-
terquartile range]), children with AD had higher levels (143.0
[52.7–601.5 kU/L]) than those of the control group (31.0
[14.2–82.4 kU/L]) in this study, with p < 0.001. There was no
difference in neutrophil counts between the two groups. De-
mographic, blood count, and serum total IgE data are pre-
sented in Table 1.
Comparison of IL-17F between AD
and control groups
The serum IL-17F level (median [interquartile range]) of
children with AD (5.96 ng/mL [2.10–15.80 ng/mL]) was
significantly higher than that of the controls (3.13 ng/mL
[0.95–8.75 ng/mL]), with p = 0.005 (Fig. 1A). IL-17F was
also significantly higher in the sera of patients with moderate
(6.41 ng/mL [2.24–19.9 ng/mL]; p= 0.001]) and severe AD
Table 1. Demographics of Subjects
Atopic dermatitis
Control (n = 62) Mild (n= 50) Moderate (n = 49) Severe (n = 129) p-Value
Sex (M/F) 32/30 32/18 30/19 88/41 0.171
Age (years) 7.93 – 3.9
(0.5–17.3)
4.91 – 3.5
(0.5–13.0)
3.42 – 3.4
(0.5–10.6)
5.4 – 4.1
(0.5–16.8)
< 0.001 *
White blood cells (/mL) 7,175
(6,180–8,732)
8,635
(7,150–10,562)
9,670
(7,555–12,030)
9,165
(7,467–11,945)
< 0.001 *
Blood eosinophils (/mL) 170 (100–275) 450 (240–742) 410 (240–670) 490 (320–970) < 0.001 *
Blood neutrophils (/mL) 3,290
(2,720–4,280)
2,680
(2,015–4,625)
2,650
(1,830–4,110)
3,340
(2,495–4,125)
0.299
Serum total IgE (kU/L) 31.0
(14.2–82.4)
134.0
(56.0–362.0)
73.6
(23.5–294.0)
233.0
(77.4–929.0)
< 0.001 *
SCORAD 11.0 – 2.4 (7–15) 24.2 – 8.2 (16–39) 57.4– 13.3 (40–89) < 0.001 {
Data are represented as mean– standard deviation (min–max) or median (interquartile range). p-Values were calculated in the adjusted
analysis using multiple linear regression with an adjustment for age. A p-value of< 0.05 was considered statistically significant.
*Control group is different from AD group. {Differences between each of the three severity categories and the control group.
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(7.65 ng/mL [2.90–18.0 ng/mL]; p < 0.001) than in those with
mild AD (1.17 ng/mL [0.34–8.73 ng/mL]; Fig. 1B).
Correlation of serum IL-17F levels with total IgE
levels and disease severity
In the AD group, total IgE levels were positively correlated
with SCORAD (r= 0.257, p= 0.005; Fig. 2A). Similarly,
serum IL-17F was positively correlated with SCORAD in the
AD group (r= 0.284, p= 0.002; Fig. 2B). However, there was
no correlation between serum IL-17F levels and serum total
IgE levels, blood eosinophil counts, or neutrophil counts.
Discussion
IL-17A (also called IL-17) is the founding member and the
best studied among the IL-17 family cytokines.14 Besides
being produced byTh17 cells, IL-17 is produced by a variety of
cell types, including gd T cells, NKT cells, NK cells, neutro-
phils, and eosinophils.15 The IL-17F gene was discovered in
2001, and is located on chromosome 6p12.16 IL-17A and IL-
17F genes are localized in the same chromosome region, and
IL-17F shares the strongest homology to IL-17A.17,18 How-
ever, IL-17F seems to function differently from IL-17A in
immune response and disease. Interestingly, IL-17A and IL-
17F appear to have opposite functions in chronic allergic air-
way diseases. While IL-17A deficiency reduced expression of
Th2 cytokines, IL-17F deficiency enhanced Th2 cytokine ex-
pression and eosinophil function in mice.19 In AD, few studies
on the role of IL-17 family cytokines have been performed. An
association between SCORAD score and IL-17 (IL-17A) lev-
els (M= 32.60 pg/mL, range 28.55–37.85 pg/mL) has been
reported previously in a study of a Chinese population.20 In the
present study, serum IL-17F levels were significantly higher in
children with AD than they were in healthy children. The re-
sults also showed that IL-17F is positively correlated with AD
severity. As IL-17F has been reported to be involved in re-
cruitment and activation of neutrophils, the study investigated
whether the expression of this cytokines correlates with the
blood neutrophil counts.15 However, no correlation was found
between serum IL-17F level and blood neutrophil counts.
FIG. 1. Interleukin (IL)-
17F levels in the sera. (A)
Serum IL-17F levels in pa-
tients with atopic dermatitis
(AD) were higher than those
in control subjects. (B) Ser-
um IL-17F levels by disease
severity among AD patients.
*p < 0.05; **p < 0.001.
FIG. 2. (A) Correlation of serum total IgE (kU/L) levels
with the SCORing Atopic Dermatitis (SCORAD) tool in
children with AD. (B) Correlation of serum IL-17F (ng/mL)
levels with SCORAD in children with AD.
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Hayashida et al. reported that the IL-17+ T cell subset in AD
correlated with the levels of IgE and eosinophilia.3 However,
the present study found no correlation between serum IL-17F
levels and serum total IgE or blood eosinophil counts.
AD is characterized by impairment in epidermal barrier
function and abnormal immunologic cytokine expression in the
skin and peripheral blood.Recent studies on the skin barrier role
in the development of AD corroborate an ‘‘outside–inside’’
hypothesis.21 The barrier dysfunction in AD involves twomain
components: decreased generation of filaggrin and tight junc-
tion defects.21 Gutowska-Owsiak et al. reported a significant
decrease in profilaggrin mRNA levels of keratinocytes after
cultures were exposed to IL-17A. In addition to Th1/Th2 bias
that influences expression of filaggrin, increased IL-17A may
reduce the expression of filaggrin in keratinocytes.22 Con-
stitutive expression of an IL-17 receptor in keratinocytes has
been previously reported.23 Filaggrin-deficient mice were
shown to possess increased IL-17mRNA levels in skin lesions
shortly after epicutaneous application of OVA.24 In light of
these findings, it appears that abnormal IL-17F expression in the
skin may contribute to barrier dysfunction and lead to an in-
crease in antigen penetration and priming of specific T cells.25
However, the possibility cannot be excluded that eleva-
tion of IL-17F follows dysregulated immunity in AD. IL-
17F is produced by cells of both the innate and adaptive
responses, suggesting a bridging function between the two.
In the skin, IL-17 is a master regulator of antimicrobial
peptides (AMPs) and plays a central role in host defense of
keratinocytes.26,27 Niebuhr et al. showed that a-toxins from
Staphylococcus aureus induce IL-17 production in Th17
cells from atopic individuals.28 Increased expression of IL-
17 that exacerbates the inflammatory response may further
contribute to the chronic nature of AD.
The present data indicate that IL-17F may play a role in
the pathogenesis of AD. However, this study has some
limitations. There were no functional or bioptical assess-
ments of patients. For this reason, further studies should be
conducted to examine the pathogenic role of IL-17F in AD.
Conclusion
In summary, this study investigated serum IL-17 levels in
children with AD. Serum IL-17F levels are significantly
increased in children with AD relative to a control, and IL-
17F levels correlate with AD severity. The study suggests
that serum IL-17F may play a role in AD pathogenesis.
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